Parkinson's breakthrough? stem cells show promise in early trial

NCT ID NCT05887466

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested a new stem cell treatment for Parkinson's disease in 12 people who had been diagnosed at least 5 years earlier. The treatment uses dopamine-producing cells made from embryonic stem cells, injected into the brain. The main goal was to check safety, but researchers also looked for signs that it might slow or reverse the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
embryonic stem cell-derived dopamine progenitor cells
What this could lead to
If this works, it could point toward a treatment that slows or stops Parkinson's progression, or even helps repair damaged brain areas.
What could go wrong
This is a very early, small trial (12 people) focused mainly on safety. The treatment may not work, and there are risks like tumors or immune reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Yonsei University Health System, Severance Hospital

    Seoul, 03722, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.